CYBN.NE stock plunged 30.12% to C$7.40 on 06 Mar 2026 during market hours on the NEO exchange in Canada. The drop followed a gap down from a previous close of C$10.59, with an intraday low of C$7.30 and volume of 19,396 shares. Cybin Inc. (CYBN.NE) now trades below its 50-day average of C$9.28 and 200-day average of C$9.60, leaving near-term support at the year low of C$6.95. This article breaks down the drivers, valuation, technical levels and model forecasts for traders watching top losers today.

Market move and immediate drivers for CYBN.NE stock

Cybin Inc. (CYBN.NE) fell 30.12% after opening at C$7.83 and trading as low as C$7.30, reflecting a sharp re-pricing from the prior close of C$10.59. Volume at 19,396 was roughly in line with the average volume of 19,421, suggesting focused selling rather than a broad exit. Market commentary flagged potential listing concerns and volatility in psychedelic biotech names as the main catalyst for today’s sell-off. For traders, the immediate story is correction risk rather than a liquidity shock: market cap sits at C$280,787,048 with 24,205,780 shares outstanding.

Fundamentals and valuation snapshot for Cybin Inc.

Cybin reports EPS of -5.17 and a trailing PE of -2.24, reflecting ongoing negative earnings in its R&D-heavy biotech model. Key balance metrics show cash per share C$4.59 and book value per share C$6.44, producing a price-to-book of 1.32, below many healthcare peers. The company shows a current ratio of 13.78, signaling short-term solvency, but negative operating cash flow per share of -2.75 highlights funding burn. These fundamentals explain why CYBN.NE stock trades at a discount to growth peers despite binary clinical catalysts ahead.

Technical picture and short-term trading levels for CYBN.NE stock

Technicals show oversold bias: RSI 39.81, CCI -153.48, and price near the Bollinger lower band at C$7.65 middle band C$9.61. ADX 29.20 signals a strong trend, and ATR C$1.07 implies elevated intraday volatility. Immediate support lies at the year low C$6.95 and psychological round number C$6.00; resistance sits at the 50-day average C$9.28 and prior close C$10.59. Traders should watch the MACD histogram small negative reading and on‑balance volume for signs of distribution or accumulation.

Meyka AI rating and model forecast for CYBN.NE

Meyka AI rates CYBN.NE with a score of 62.78 out of 100 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector and industry performance, financial growth, key metrics, forecasts, and analyst consensus. Meyka AI’s forecast model projects a monthly price near C$7.87 and a quarterly level around C$8.01, implying upside of about 6.35% and 8.24% versus the current price C$7.40. Forecasts are model-based projections and not guarantees.

Risks and catalysts shaping CYBN.NE outlook

Key near-term risks include regulatory or listing developments, clinical trial updates, and continued sector rotation away from speculative biotech names. Catalysts that could reverse the trend include positive trial readouts for CYB003, licensing deals, or clearer listing status. Financially, cash runway is sensitive to R&D spend: free cash flow per share is -2.80, so financing events would materially affect valuation. Investors should weigh binary clinical timeline events versus a tight cash burn profile.

Analyst views and sector context for CYBN.NE stock

Sell-side and data providers show mixed signals: a recent company rating flagged a C / Sell view on 04 Mar 2026, while broader market commentary lists CYBN among volatile psychedelic biotech names. In the Healthcare sector, average price-to-book is about 2.43, so Cybin’s P/B 1.32 is comparatively low. Sector weakness today amplified CYBN.NE losses; watch sector flow and peer trial results for directional cues. For balanced perspective, consult evolving analyst updates and official company releases.

Final Thoughts

Cybin Inc. (CYBN.NE) is a top loser in today’s market hours, dropping to C$7.40 on 06 Mar 2026 after a gap from C$10.59. The sell-off compresses near-term support to the year low C$6.95, while resistance appears at the 50-day average C$9.28 and the prior close C$10.59. Fundamentals show negative EPS -5.17 and negative cash flow per share, offset by ample book value C$6.44 and strong current liquidity ratios. Meyka AI rates CYBN.NE 62.78/100 (B, HOLD) and flags both clinical upside and financing risk. Meyka AI’s forecast model projects C$7.87 (monthly) and C$8.01 (quarterly), implying modest upside of 6.35% and 8.24% from the current price C$7.40. These model figures are not guarantees and should be combined with catalyst monitoring, risk management, and official filings. Traders watching top losers should treat CYBN.NE as a high-volatility biotech, where short-term setups hinge on clearer news flow or technical stabilization above C$9.28.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.